GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nykode Therapeutics AS (OSL:NYKD) » Definitions » Equity-to-Asset

Nykode Therapeutics AS (OSL:NYKD) Equity-to-Asset : 0.85 (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Nykode Therapeutics AS Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Nykode Therapeutics AS's Total Stockholders Equity for the quarter that ended in Sep. 2024 was kr1,515.20 Mil. Nykode Therapeutics AS's Total Assets for the quarter that ended in Sep. 2024 was kr1,788.98 Mil. Therefore, Nykode Therapeutics AS's Equity to Asset Ratio for the quarter that ended in Sep. 2024 was 0.85.

The historical rank and industry rank for Nykode Therapeutics AS's Equity-to-Asset or its related term are showing as below:

OSL:NYKD' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.71   Med: 0.79   Max: 0.95
Current: 0.85

During the past 7 years, the highest Equity to Asset Ratio of Nykode Therapeutics AS was 0.95. The lowest was 0.71. And the median was 0.79.

OSL:NYKD's Equity-to-Asset is ranked better than
74.54% of 1512 companies
in the Biotechnology industry
Industry Median: 0.67 vs OSL:NYKD: 0.85

Nykode Therapeutics AS Equity-to-Asset Historical Data

The historical data trend for Nykode Therapeutics AS's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nykode Therapeutics AS Equity-to-Asset Chart

Nykode Therapeutics AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.83 0.78 0.73 0.71 0.82

Nykode Therapeutics AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.75 0.82 0.83 0.85 0.85

Competitive Comparison of Nykode Therapeutics AS's Equity-to-Asset

For the Biotechnology subindustry, Nykode Therapeutics AS's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nykode Therapeutics AS's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nykode Therapeutics AS's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Nykode Therapeutics AS's Equity-to-Asset falls into.



Nykode Therapeutics AS Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Nykode Therapeutics AS's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=1806.68/2196.227
=0.82

Nykode Therapeutics AS's Equity to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

Equity to Asset (Q: Sep. 2024 )=Total Stockholders Equity/Total Assets
=1515.197/1788.984
=0.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nykode Therapeutics AS  (OSL:NYKD) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Nykode Therapeutics AS Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Nykode Therapeutics AS's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Nykode Therapeutics AS Business Description

Traded in Other Exchanges
Address
Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need.

Nykode Therapeutics AS Headlines

No Headlines